LifeMD's Q2 results reveal pressure from higher customer acquisition costs.
PorAinvest
viernes, 29 de agosto de 2025, 10:06 am ET1 min de lectura
LFMD--
LifeMD's shares plummeted $5.31 (-44%) on August 6, 2025, after the company reported missing consensus GAAP EPS and revenue estimates. The earnings call revealed higher-than-expected refund rates and elevated customer acquisition costs, particularly in the RexMD segment, which focuses on men's health [1].
The investigation, led by Hagens Berman partner Reed Kathrein, centers on LifeMD's May 6, 2025, earnings call, where the company raised its full-year 2025 revenue and adjusted EBITDA guidance. The complaint alleges that LifeMD made false and misleading statements while failing to disclose crucial information, including rising customer acquisition costs and costs related to the sale of obesity drugs [1].
KeyBanc analyst, in a recent report, criticized LifeMD's management for its "overly optimistic" guidance and "lack of transparency" regarding operational challenges. The analyst advised investors to exercise caution and closely monitor the company's future earnings reports [2].
Investors who purchased LifeMD securities between May 7, 2025, and August 5, 2025, are encouraged to submit their losses and contact Hagens Berman or Johnson Fistel, PLLP for further information. The lead plaintiff deadline is October 27, 2025 [1, 2].
References:
[1] https://www.marketscreener.com/news/lifemd-inc-lfmd-hit-with-securities-class-action-after-shares-crash-44-on-q2-2025-earnings-surp-ce7c50dfd18df621
[2] https://www.globenewswire.com/news-release/2025/08/28/3141185/0/en/LifeMD-Inc-Shareholders-Who-Lost-Money-on-Their-Investment-are-Encouraged-to-Contact-Johnson-Fistel-about-the-Class-Action-Lawsuit.html
• LifeMD under investigation for securities fraud and unlawful practices. • Company reports higher customer acquisition costs in Q2 2025. • RexMD platform focused on men's health. • KeyBanc analyst criticizes LifeMD's management.
LifeMD Inc. (LFMD), a company focused on virtual obesity care, is currently under investigation for potential securities fraud and unlawful practices. The probe, initiated by prominent shareholder rights firm Hagens Berman, follows the company's disappointing Q2 2025 financial results and subsequent stock price crash [1].LifeMD's shares plummeted $5.31 (-44%) on August 6, 2025, after the company reported missing consensus GAAP EPS and revenue estimates. The earnings call revealed higher-than-expected refund rates and elevated customer acquisition costs, particularly in the RexMD segment, which focuses on men's health [1].
The investigation, led by Hagens Berman partner Reed Kathrein, centers on LifeMD's May 6, 2025, earnings call, where the company raised its full-year 2025 revenue and adjusted EBITDA guidance. The complaint alleges that LifeMD made false and misleading statements while failing to disclose crucial information, including rising customer acquisition costs and costs related to the sale of obesity drugs [1].
KeyBanc analyst, in a recent report, criticized LifeMD's management for its "overly optimistic" guidance and "lack of transparency" regarding operational challenges. The analyst advised investors to exercise caution and closely monitor the company's future earnings reports [2].
Investors who purchased LifeMD securities between May 7, 2025, and August 5, 2025, are encouraged to submit their losses and contact Hagens Berman or Johnson Fistel, PLLP for further information. The lead plaintiff deadline is October 27, 2025 [1, 2].
References:
[1] https://www.marketscreener.com/news/lifemd-inc-lfmd-hit-with-securities-class-action-after-shares-crash-44-on-q2-2025-earnings-surp-ce7c50dfd18df621
[2] https://www.globenewswire.com/news-release/2025/08/28/3141185/0/en/LifeMD-Inc-Shareholders-Who-Lost-Money-on-Their-Investment-are-Encouraged-to-Contact-Johnson-Fistel-about-the-Class-Action-Lawsuit.html
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios